BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Monday, February 2, 2026
See today's BioWorld
Home
» Dealmaking in life sciences remains on robust pace, Recap study finds
To read the full story,
subscribe
or
sign in
.
Dealmaking in life sciences remains on robust pace, Recap study finds
Aug. 4, 2014
By
Peter Winter
Any notions that the pace of dealmaking would ease off in 2014 after the record number of M&A and licensing transactions that were completed last year, will be quickly dispelled following the release of the Thomson Reuters Recap half-year analysis.
BioWorld